Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

857 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development, Validation, and Clinical Utility of a Six-gene Signature to Predict Aggressive Prostate Cancer.
Krzyzanowska A, Barron S, Higgins DF, Loughman T, O'Neill A, Sheehan KM, Wang CA, Fender B, McGuire L, Fay J, O'Grady A, O'Leary D, Watson RW, Bjartell A, Gallagher WM. Krzyzanowska A, et al. Among authors: fay j. Eur Urol Focus. 2023 Nov;9(6):983-991. doi: 10.1016/j.euf.2023.04.004. Epub 2023 Apr 25. Eur Urol Focus. 2023. PMID: 37105783 Free article.
RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Toomey S, Eustace AJ, Pritzker LB, Pritzker KP, Fay J, O'Grady A, Cummins R, Grogan L, Kennedy J, O'Connor D, Young L, Kay EW, O'Donovan N, Gallagher WM, Kalachand R, Crown J, Hennessy BT. Toomey S, et al. Among authors: fay j. J Natl Cancer Inst. 2016 Jul 4;108(8):djw111. doi: 10.1093/jnci/djw111. Print 2016 Aug. J Natl Cancer Inst. 2016. PMID: 27377904 Free PMC article. No abstract available.
The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer.
Toomey S, Madden SF, Furney SJ, Fan Y, McCormack M, Stapleton C, Cremona M, Cavalleri GL, Milewska M, Elster N, Carr A, Fay J, Kay EW, Kennedy S, Crown J, Gallagher WM, Hennessy BT, Eustace AJ. Toomey S, et al. Among authors: fay j. Oncotarget. 2016 Nov 15;7(46):75518-75525. doi: 10.18632/oncotarget.12782. Oncotarget. 2016. PMID: 27776352 Free PMC article.
Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S, Eustace AJ, Fay J, Sheehan KM, Carr A, Milewska M, Madden SF, Teiserskiene A, Kay EW, O'Donovan N, Gallagher W, Grogan L, Breathnach O, Walshe J, Kelly C, Moulton B, Kennedy MJ, Gullo G, Hill AD, Power C, Duke D, Hambly N, Crown J, Hennessy BT. Toomey S, et al. Among authors: fay j. Breast Cancer Res. 2017 Jul 27;19(1):87. doi: 10.1186/s13058-017-0883-9. Breast Cancer Res. 2017. PMID: 28750640 Free PMC article. Clinical Trial.
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples.
Toomey S, Carr A, Mezynski MJ, Elamin Y, Rafee S, Cremona M, Morgan C, Madden S, Abdul-Jalil KI, Gately K, Farrelly A, Kay EW, Kennedy S, O'Byrne K, Grogan L, Breathnach O, Morris PG, Eustace AJ, Fay J, Cummins R, O'Grady A, Kalachand R, O'Donovan N, Kelleher F, O'Reilly A, Doherty M, Crown J, Hennessy BT. Toomey S, et al. Among authors: fay j. J Transl Med. 2020 Feb 22;18(1):99. doi: 10.1186/s12967-020-02273-4. J Transl Med. 2020. PMID: 32087721 Free PMC article.
Human Epidermal Growth Factor Receptor-3 Expression Is Regulated at Transcriptional Level in Breast Cancer Settings by Junctional Adhesion Molecule-A via a Pathway Involving Beta-Catenin and FOXA1.
Cruz RGB, Madden SF, Richards CE, Vellanki SH, Jahns H, Hudson L, Fay J, O'Farrell N, Sheehan K, Jirström K, Brennan K, Hopkins AM. Cruz RGB, et al. Among authors: fay j. Cancers (Basel). 2021 Feb 19;13(4):871. doi: 10.3390/cancers13040871. Cancers (Basel). 2021. PMID: 33669586 Free PMC article.
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
Mezynski MJ, Farrelly AM, Cremona M, Carr A, Morgan C, Workman J, Armstrong P, McAuley J, Madden S, Fay J, Sheehan KM, Kay EW, Holohan C, Elamin Y, Rafee S, Morris PG, Breathnach O, Grogan L, Hennessy BT, Toomey S. Mezynski MJ, et al. Among authors: fay j. J Transl Med. 2021 May 1;19(1):184. doi: 10.1186/s12967-021-02842-1. J Transl Med. 2021. PMID: 33933113 Free PMC article.
The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer.
Eustace AJ, Madden SF, Fay J, Collins DM, Kay EW, Sheehan KM, Furney S, Moran B, Fagan A, Morris PG, Teiserskiene A, Hill AD, Grogan L, Walshe JM, Breathnach O, Power C, Duke D, Egan K, Gallagher WM, O'Donovan N, Crown J, Toomey S, Hennessy BT. Eustace AJ, et al. Among authors: fay j. Breast Cancer Res Treat. 2021 Jun;187(3):635-645. doi: 10.1007/s10549-021-06244-1. Epub 2021 May 13. Breast Cancer Res Treat. 2021. PMID: 33983492 Free PMC article.
Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
Lynch SM, Russell NM, Barron S, Wang CA, Loughman T, Dynoodt P, Fender B, Lopez-Ruiz C, O'Grady A, Sheehan KM, Fay J, Amberger-Murphy V, Saha A, Klinger R, Gonzalez CA, Al-Attar N, Rahman A, O'Leary D, Lanigan FT, Bracken AP, Crown J, Kelly CM, O'Connor DP, Gallagher WM. Lynch SM, et al. Among authors: fay j. Eur J Cancer. 2021 Jul;152:78-89. doi: 10.1016/j.ejca.2021.04.016. Epub 2021 Jun 2. Eur J Cancer. 2021. PMID: 34090143 Free article.
857 results